 NextCure, Inc. NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the companys clinical trial activities due to the impact of the COVID-19 pandemic. The COVID-19 pandemic has put significant strain on our clinical trial sites, and has raised concerns around monitoring patient safety, said Michael Richman, NextCures president and chief executive officer. 